3105 Purpose: Pittsburgh compound-B positron emission tomography (PiB-PET)
quantitatively measures amyloid-β accumulation and fluorodeoxy-D-glucose PET (FDG …

Objectives The aim of this article was to review the current role of brain PET in the diagnosis
of Alzheimer dementia. The characteristic patterns of glucose metabolism on brain FDG-PET …

3015 Introduction: For diagnosis of Alzheimer9s disease (AD), carbon-11 (11 C)-labeled
Pittsburgh compound‐B positron emission tomography (PiB-PET) and 18 F …

Purpose The value of imaging regional glucose metabolism with [18 F] FDG PET for the
prediction of progression from mild cognitive impairment (MCI) to Alzheimer's dementia (AD) …

1061 Background: The incidence of dementia in elderly population has been rapidly
increasing and causes significant burden on quality of lives, socio-economy and healthcare …

Background: Amyloid imaging with positron emission tomography (PET) often comes with
glucose metabolic imaging in diagnosis of Alzheimer's disease (AD). Objective: The present …

Beta amyloid plaques, neurofibrillary tangles, and impaired glucose metabolism are among
the most prevalent pathological characteristics of Alzheimer's disease (AD). However …

The purpose of this study was to compare the diagnostic accuracy of glucose metabolism
and amyloid deposition as demonstrated by 18F-FDG and Pittsburg Compound B (PiB) PET …

Purpose Cerebral beta-amyloid and regional glucose metabolism assessed by positron
emission tomography (PET) are used as diagnostic biomarkers for Alzheimer's disease …

We conducted a meta-analysis of positron emission tomography (PET) findings in
Alzheimer's disease (AD) and mild cognitive impairment (MCI) to clarify the changes …